CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Therapy in men with low-risk to intermediate to high-risk localized prostate cancer who are candidates for, or have opted for, pros...
Taipei, Taiwan and 32 other locations
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2...
Phase 1
Taipei, Taiwan and 52 other locations
second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate...
Phase 3
Taipei, Taiwan and 87 other locations
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alon...
Phase 3
Taipei, Taiwan and 56 other locations
therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Coho...
Phase 1, Phase 2
Taipei, Taiwan and 27 other locations
To evaluate the effect of MCS® compared with placebo in reducing the risk of biopsy-detectable prostate cancer in high-risk subject...
Phase 2
Taipei, Taiwan
compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate...
Phase 3
Taipei, Taiwan and 231 other locations
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate...
Phase 3
Taipei, Taiwan and 388 other locations
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutam...
Phase 2
Taipei, Taiwan and 235 other locations
plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the doce...
Phase 3
Taipei, Taiwan and 216 other locations
Clinical trials
Research sites
Resources
Legal